Juno Therapeutics is a pioneer in chimeric antigen receptor T-cell (CAR-T) immunotherapy, a promising new approach to cancer treatment. Founded in 2013, Juno quickly attracted major investments from leading healthcare firms due to its innovative CAR-T pipeline. After going public in 2014, Juno continued to receive large investments from companies like Celgene, eventually leading to its $9 billion acquisition by Celgene in 2018. Juno’s rise highlights the vast potential and intense competition in CAR-T research. This article examines Juno’s major investments over the years and analyzes what the future may hold for this emerging immunotherapy leader.
Juno’s Blockbuster IPO Attracted Early Investments
Juno completed a successful IPO in 2014, raising over $250 million. This provided validation and capital to advance Juno’s pipeline of CAR-T therapies. Major early-stage investors in Juno included ARCH Venture Partners, Alaska Permanent Fund, and Amazon founder Jeff Bezos.
Celgene’s Initial Investment Propelled Juno’s Growth
A $1 billion investment from Celgene in 2015 was a key turning point, providing funding for Juno to enhance its CAR-T manufacturing capabilities. This deal also involved a collaboration on CAR-T clinical trials.
Bristol Myers Squibb Fought for Control of Juno
Juno agreed to a $9 billion buyout by Celgene in early 2018. However, Bristol Myers Squibb put in a competing bid for Juno, offering $1 billion more. This highlighted Juno’s leadership in CAR-T research and the fierce competition among pharma giants.
From its founding to acquisition, Juno exemplified the vast promise and rapid evolution of CAR-T immunotherapy. Major investments from leading healthcare firms fueled Juno’s rise as a CAR-T pioneer and enabled its pipeline advancements. Juno’s legacy continues through its parent company Celgene, now a division of Bristol Myers Squibb.